Infinity Pharmaceuticals, Inc., (INFI $2.66) a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma , which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/ or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was in corporated in 2000 and is headquartered in Cambridge, Massachusetts.
Followings are bullish reasons for INFI:
1.Infinity Pharmaceutical Inc. (INFI) has achieved Fast Track designation from the U.S. Food and Drug Administration (FDA) for Eganelisib in both breast cancer and Erothelial cancer. It has been working with pharmaceutical giants Bristol Myer Squibb (BMY) and Roche Holdings (RHHBY) on the above developments. Infinity release last week of clinical trial data for its oncology drug candidate eganelisib. The company divulged that in a phase 2 trial, eganelisib was found to be rather efficacious when used in combination therapy for urothelial cancer. Specifically, "the data showed that eganelisib increased overall survival in patients with metastatic urothelial cancer and prolonged progression free survival in patients with breast cancer."
2. JPMorgan raised its Neutral rating to Overweight with a $6 price target. Wells Fargo started coverage on Infinity Pharmaceuticals stock on July 28 and has a huge $14 price target. On July 7, B. Riley put price target at $7, The average of these latest 3 targets is $9.
3. 58.5% of stocks are institution own，plenty of institutional sponsorship. Only 86.79 million shares float.
4.Very healthy financials: 9.4 Current Ratio, no Long Term Debt, Cash/Share $1.
5. Technicals: On July 28, good news drove stock gapped up and closed up 61% with 172 million shares traded, 28 times more than average and is very strong upside momentum. It then retraced two days only to surge up again by 38% yesterday with 75 million shares traded, over 11 times average volume. It came down 9% today but with only 2.4 times average volume. Low trading volume is bullish for stock since it means people are reluctant to sell. It was down 17% at the low of today but it cut the losses down to 9% at the close, this buy on dip action is also bullish for stock. INFI near term support is $2.4 and near term resistances are $3 and $3.5. Longer term will likely be a 3 bagger.
Conclusion: INFI is very attractive at this level ($2.66) as average analyst target price is 9. With 58% institution ownership , solid financial situation and strong price actions also bode well with the stock.
Infinity Pharmaceuticals, Inc. (INFI $2.66) 是一家生物制药公司，专注于为癌症患者开发新药。其候选产品是 IPI-549，一种口服的临床阶段免疫肿瘤产品候选药，可抑制磷酸肌醇-3-激酶-γ，该产品处于 1/1b 期临床试验阶段，用于治疗三阴性乳腺癌、固体肿瘤和卵巢癌。该公司与 Intellikine, Inc. 建立了战略联盟，以发现、开发和商业化针对 PI3K 的 delta 和/或 gamma 异构体的药品； Verastem, Inc. 研究、开发、商业化和制造 duvelisib 和含有 duvelisib 的产品；和 PellePharm, Inc. 开发和商业化其刺猬抑制剂项目 IPI-926（临床阶段候选产品）的权利，以及与 Arcus Biosciences, Inc.、F. Hoffmann-La Roche Ltd. 和 Bristol Myer Squibb 等的合作协。 Infinity Pharmaceuticals, Inc. 于 2000 年成立，总部位于马萨诸塞州剑桥。
以下是 INFI 的看涨理由：
1. Infinity Pharmaceutical Inc. (INFI) 已获得美国食品和药物管理局 (FDA) 对 Eganelisib 治疗乳腺癌和上皮癌的快速通道指定。它一直在与制药巨头Bristol Myer Squibb (BMY) 和罗氏控股 (RHHBY) 就上述发展进行合作。Infinity 上周发布了其肿瘤药物候选药物 eganelisib 的临床试验数据。 该公司透露，在一项 第2 期试验中，发现 eganelisib 在用于尿路上皮癌的联合治疗时相当有效。具体来说，“数据显示 eganelisib 增加了转移性尿路上皮癌患者的总生存期，并延长了 乳腺癌患者的无进展生存期。”
2. 8月2日摩根大通将中性评级上调至增持，目标价为 6 美元。富国银行于 7 月 28 日开始跟踪Infinity Pharmaceuticals 的股票，目标价定为 14 美元。 7 月 7 日，B. Riley 将目标价定为 7 美元，这三个最新目标的平均价为 9 美元。
3. 58.5%的股票为机构持有，机构赞助充足。INFI只有8679万股流通。
4. 非常健康的财务状况：流动比率为 9.4，无长期债务，现金/股价为1 美元。
5. 技术面：7月28日利好消息带动股价跳空收涨61%，成交量为1.72亿股，是平均量的28倍，上涨势头非常强劲。然后它回撤两天，昨天再次飙升 38%，交易量为 7500 万股，是平均成交量的 11 倍。今天它下跌了 9%，但交易量只是平均成交量的 2.4 倍。低交易量回调对股票有利，因为这意味着人们不愿意卖出股票。它在今天的低点时曾下跌了 17%，但在收盘时将跌幅缩小至 9%，这种逢低买入的行为也对股票有利。 INFI 近期支撑位为 2.4 美元，近期阻力位为 3 美元和 3.5 美元。长期价位可能是现在的3倍。
结论：INFI 在这个水平（2.66 美元）上非常有吸引力，因为分析师的平均目标价是 9。58% 的机构持股，稳固的财务状况和强劲的价格走势也预示着该股票的继续上涨。
No comments:
Post a Comment